Estrogen metabolites and the risk of breast cancer in older women

Epidemiology

Volumn 14, Issue 6, 2003, Pages 740-744

  Cauley, Jane A ^a,e   Zmuda, Joseph M ^a   Danielson, Michelle E ^a   Ljung, Britt Marie ^b   Bauer, Douglas C ^c   Cummings, Steven R ^d   Kuller, Lewis H ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

Breast cancer; Estrogen; Estrogen metabolites

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTROGEN DERIVATIVE; 16 HYDROXYESTRONE; 16-HYDROXYESTRONE; 2-HYDROXYESTRONE; ESTROGEN; ESTRONE DERIVATIVE; STEROID 16ALPHA MONOOXYGENASE;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; ESTROGEN METABOLISM; FAMILY HISTORY; FEMALE; FIBROCYSTIC BREAST DISEASE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; OBESITY; PRIORITY JOURNAL; SMOKING; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; METABOLISM; QUESTIONNAIRE; RISK FACTOR;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGENS; FEMALE; HUMANS; HYDROXYESTRONES; QUESTIONNAIRES; RISK FACTORS; STEROID 16-ALPHA-HYDROXYLASE;

EID: 1542682252     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000091607.77374.74     Document Type: Article

References (24)

1. The Endogenous Hormones, Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606-616.
2. Zhu B, Conney A. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19:1-27.
3. Bradlow H, Hershcopf R, Martucci C, et al. Estradiol 16α- hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A. 1985;82:6295-6299.
4. Bradlow H, Herschcopf R, Martucci C, et al. 16α-hydroxylation of estradiol: a possible risk marker for breast cancer. Ann NY Acad Sci. 1986;464:138-151.
5. Schneider J, Kinne D, Fracchia A, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A. 1982;79:3047-3051.
6. Ho G, Luo X, Ji C, et al. Urinary 2/16α-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore. 1998;27: 294-299.
7. Kabat G, Chang C, Sparano J, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 1997;6:1-6.
8. Zheng W, Dunning L, Jin F, et al. Urinary estrogen metabolites and breast cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 1997;6:500-504.
9. Ursin G, London S, Stanczyk F, et al. Urinary 2-hydroxyestrone/16α- hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999;91:1067-1072.
10. Osborne M, Bradlow L, Wong G, et al. Upregulation of estradiol C16a-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst. 1993;85:1917-1920.
11. Meilahn E, Stavola B, Allen D, et al. Do urinary estrogen metabolites predict breast cancer? Br J Cancer. 1998;78:1250-1255.
12. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11: 635-640.
13. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773.
14. Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130:270-277.
15. Zmuda J, Cauley J, Ljung BM, et al. Bone mass and breast cancer risk in older women: differences by stage of diagnosis. J Natl Cancer Inst. 2001;93:930-936.
16. Klug T, Bradlow H, Sepkovic D. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16α-hydroxyestrone in urine. Steroids. 1994;59:648-655.
17. Ziegler R, Rossi S, Fears T, et al. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16α-hydroxyestrone in urine. Environ Health Perspect. 1997;105(suppl 3):607-614.
18. Prentice R. A case-control design for epidemiologic cohort studies and disease prevention trials. Biometricka. 1986;73:1-11.
19. Bradlow H, Telang N, Sepkovic D, et al. 2-hydroxyestrone: the 'good' estrogen. J Endocrinol. 1996;150:S259-S265.
20. Fishman J, Martucci C. Biological properties of 16alpha-hydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab. 1980;51:611-615.
21. Hankinson S, Willett W, Colditz GA, et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet. 1998;351: 1393-1396.
22. Zhu B, Bui Q, Weisz J, et al. Conversion of estrone to 2- and 4-hydroxyestrone by hamster kidney and liver microsomes: implications for the mechanism of estrogen-induced carcinogenesis. Endocrinology. 1994;135:1772-1779.
23. Liehr J, Ricci M. 4-hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci U S A. 1996;93:3294-3296.
24. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute; 2002. http://seer.cancer. gov/csr/1973_1999/. Accessed July 8, 2003.